

SM1225R**Monoclonal Antibody to HLA Class II DP, DR, DQ - PE**

Alternate names:	DQ, DQ, DR, DR, HLA class II histocompatibility antigen DP, MHC class II antigen DP
Quantity:	100 Tests
Background:	The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.
Host / Isotype:	Mouse / IgG2a
Clone:	WR18
Immunogen:	Human HLA Class II (DP, DQ, DR). Spleen cells from an immunised BALB/c mice were fused with cells of the mouse NS0 mouse myeloma cell line.
Format:	State: Lyophilized purified IgG fraction Purification: Affinity Chromatography on Protein G Buffer System: PBS, pH 7.4 containing 0.09% Sodium Azide and 0.1% Bovine Serum Albumin Preservatives: 0.09% Sodium Azide Stabilizers: 0.1% BSA Label: PE – R. Phycoerythrin (RPE) Reconstitution: Restore with 1 ml distilled water
Applications:	Flow Cytometry: Use 10 µl of neat antibody to label 10 ⁶ cells or 100 µl whole blood. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	This antibody recognizes a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes. Species: Human. Other species not tested.
Storage:	Prior to and following reconstitution store the antibody at 2-8°C. DO NOT FREEZE! This product is photosensitive and should be protected from light. Shelf life: one year from despatch.
General Readings:	1. Moore K, Cooper SA, Jones DB. Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol. 1987 May;152(1):13-21. PubMed PMID: 3305845. 2. Kissner TL, Ruthel G, Alam S, Ulrich RG, Fernandez S, Saikh KU. Activation of MyD88 signaling upon staphylococcal enterotoxin binding to MHC class II molecules. PLoS One. 2011 Jan 20;6(1):e15985. doi: 10.1371/journal.pone.0015985. PubMed PMID: 21283748. 3. Chia JS, You CM, Hu CY, Chiang BL, Chen JY. Human T-cell responses to the glucosyltransferases of Streptococcus mutans. Clin Diagn Lab Immunol. 2001

Mar;8(2):441-5. PubMed PMID: 11238236.

4. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. *Blood*. 2008 May 15;111(10):5054-63. doi: 10.1182/blood-2007-12-130609. Epub 2008 Mar 18. PubMed PMID: 18349319.

5. Litzinger MT, Foon KA, Sabzevari H, Tsang KY, Schlom J, Palena C. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. *Cancer Immunol Immunother*. 2009 Jun;58(6):955-65. doi: 10.1007/s00262-008-0611-5. Epub 2008 Nov 14. PubMed PMID: 19009294.

6. Sadallah S, Eken C, Martin PJ, Schifferli JA. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. *J Immunol*. 2011 Jun 1;186(11):6543-52. doi:

10.4049/jimmunol.1002788. Epub 2011 Apr 27. PubMed PMID: 21525379.

7. Sabbah S, Jagne YJ, Zuo J, de Silva T, Ahasan MM, Brander C, et al. T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. *Blood*. 2012 Mar 1;119(9):2083-92. doi: 10.1182/blood-2011-07-366476. Epub 2012 Jan 10. PubMed PMID: 22234686.

8. John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, et al. Differential effects of Paclitaxel on dendritic cell function. *BMC Immunol*. 2010 Mar 19;11:14. doi: 10.1186/1471-2172-11-14. PubMed PMID: 20302610.

9. Palmer KJ, Harries M, Gore ME, Collins MK. Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). *Clin Exp Immunol*. 2000 Mar;119(3):412-8. PubMed PMID: 10691911.

10. Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ. Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. *J Biomed Biotechnol*. 2012;2012:172420. doi: 10.1155/2012/172420. Epub 2012 Feb 7. PubMed PMID: 22505805.

11. Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM. Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. *J Immunol*. 2003 Oct 1;171(7):3697-704. PubMed PMID: 14500668.

12. Silk KM, Silk JD, Ichiryu N, Davies TJ, Nolan KF, Leishman AJ, et al. Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. *Gene Ther*. 2012 Oct;19(10):1035-40. doi: 10.1038/gt.2011.177. Epub 2011 Nov 10. PubMed PMID: 22071967.

13. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. *Arch Neurol*. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13. PubMed PMID: 18852339.

14. Keating S, Prince S, Jones M, Rowe M. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. *J Virol*. 2002 Aug;76(16):8179-88. PubMed PMID: 12134023.

15. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.

- Int J Cancer. 2000 Mar 1;85(5):618-26. PubMed PMID: 10699939.
16. Hayman MW, van Beijnen MT, Stamp LK, Spellerberg MB, O'Donnell JL. Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis? *J Immunol Methods*. 2006 Aug 31;315(1-2):19-26. Epub 2006 Jul 20. PubMed PMID: 16893550.
17. Manna, D. et al. (2012) WR18 Monoclonal Antibody: A single antibody to detect HLA DR, DP AND DQ antigens. *Abstracts/Human immunology 73:49-167 abstract 36P*.
18. Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee HG, Pfreundschuh M. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. *Cancer Immunol Immunother*. 2004 Jul;53(7):589-99. Epub 2004 Jan 23. PubMed PMID: 14745515.
19. Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, et al. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. *Int J Cancer*. 2004 Nov 20;112(4):661-8. PubMed PMID: 15382048.
20. Iking-Konert C et al. (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. *Ann Rheum Dis*. 64 10): 1436-42.
21. Llewelyn M, Sriskandan S, Peakman M, Ambrozak DR, Douek DC, Kwok WW, et al. HLA class II polymorphisms determine responses to bacterial superantigens. *J Immunol*. 2004 Feb 1;172(3):1719-26. PubMed PMID: 14734754.
22. Hönger G, Krähenbühl N, Dimeloe S, Stern M, Schaub S, Hess C. Inter-individual differences in HLA expression can impact the CDC crossmatch. *Tissue Antigens*. 2015 Apr;85(4):260-6. doi: 10.1111/tan.12537. PubMed PMID: 25786570.
23. Noble P, Vyas M, Al-Attar A, Durrant S, Scholefield J, Durrant L. High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. *Br J Cancer*. 2013 May 28;108(10):2097-105. doi: 10.1038/bjc.2013.166. Epub 2013 Apr 16. PubMed PMID: 23591201.